Abstract
Pancreatic cancer (PC) is a leading cause of cancer related deaths in United States. The lack of early symptoms results in latestage detection and a high mortality rate. Currently, the only potentially curative approach for PC is surgical resection, which is often unsuccessful because the invasive and metastatic nature of the tumor masses makes their complete removal difficult. Consequently, patients suffer relapses from remaining cancer stem cells or drug resistance that eventually lead to death. To improve the survival rate, the early detection of PC is critical.
Current biomarker research in PC indicates that a serum carbohydrate antigen, CA 19-9, is the only available biomarker with approximately 90% specificity to PC. However, the efficacy of CA 19-9 for assessing prognosis and monitoring patients with PC remains contentious. Thus, advances in technology and the detection of new biomarkers with high specificity to PC are needed to reduce the mortality rate of pancreatic cancer.
Keywords: Pancreatic cancer, biomarker, tumor progression, risk factor, CA 19-9
Current Pharmaceutical Design
Title:Advances in Biomarker Research for Pancreatic Cancer
Volume: 18 Issue: 17
Author(s): Kruttika Bhat, Fengfei Wang, Qingyong Ma, Qinyu Li, Sanku Mallik, Tze-chen Hsieh and Erxi Wu
Affiliation:
Keywords: Pancreatic cancer, biomarker, tumor progression, risk factor, CA 19-9
Abstract: Pancreatic cancer (PC) is a leading cause of cancer related deaths in United States. The lack of early symptoms results in latestage detection and a high mortality rate. Currently, the only potentially curative approach for PC is surgical resection, which is often unsuccessful because the invasive and metastatic nature of the tumor masses makes their complete removal difficult. Consequently, patients suffer relapses from remaining cancer stem cells or drug resistance that eventually lead to death. To improve the survival rate, the early detection of PC is critical.
Current biomarker research in PC indicates that a serum carbohydrate antigen, CA 19-9, is the only available biomarker with approximately 90% specificity to PC. However, the efficacy of CA 19-9 for assessing prognosis and monitoring patients with PC remains contentious. Thus, advances in technology and the detection of new biomarkers with high specificity to PC are needed to reduce the mortality rate of pancreatic cancer.
Export Options
About this article
Cite this article as:
Bhat Kruttika, Wang Fengfei, Ma Qingyong, Li Qinyu, Mallik Sanku, Hsieh Tze-chen and Wu Erxi, Advances in Biomarker Research for Pancreatic Cancer, Current Pharmaceutical Design 2012; 18 (17) . https://dx.doi.org/10.2174/13816128112092439
DOI https://dx.doi.org/10.2174/13816128112092439 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Applications of Molecularly Imprinted Polymers for Isolation of Estrogens from Environmental Water Samples
Current Analytical Chemistry Interaction of Oligomeric Breast Cancer Resistant Protein (BCRP) with Adjudin: A Male Contraceptive with Anti-Cancer Activity
Current Molecular Pharmacology Antiproliferative and Antifungal Activities of 1,3-diarylpropane-1,3-diones Commonly used as Sunscreen Agents
Letters in Drug Design & Discovery Sentinel Node Imaging
Current Medical Imaging Drug Resistance in Renal Tumors of Childhood
Current Pharmaceutical Biotechnology Renal Solute Transporters and Their Relevance to Serum Urate Disorder
Current Hypertension Reviews Pregnane X Receptor and its Potential Role in Drug Resistance in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Chitosan and Quercetin: Potential Hand in Hand Encountering Tumors in Oral Delivery System
Current Pharmaceutical Design Polyphenols: Skin Photoprotection and Inhibition of Photocarcinogenesis
Mini-Reviews in Medicinal Chemistry Endothelial Cells in Inflammation and Angiogenesis
Current Drug Targets - Inflammation & Allergy Patent Selections:
Recent Patents on Medical Imaging Targeting MET Receptor in Rhabdomyosarcoma: Rationale and Progress
Current Drug Targets siRNA Delivery with Lipid-based Systems: Promises and Pitfalls
Current Topics in Medicinal Chemistry Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Proteomics in the Search for Biomarkers of Animal Cancer
Current Protein & Peptide Science Diverse Roles of GADD45α in Stress Signaling
Current Protein & Peptide Science Merkel Cell Carcinoma – Current State and the Future
Current Cancer Therapy Reviews In Vivo Bio-imaging Using Chlorotoxin-based Conjugates
Current Pharmaceutical Design Gene Therapy to Overcome Drug Resistance in Cancer: Targeting Key Regulators of the Apoptotic Pathway
Current Gene Therapy Cu-mediated synthesis of 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-1-ones as potential inhibitors of sirtuins
Letters in Drug Design & Discovery